The Global Injectable Nanomedicines market was valued at USD 479.6 million in 2017, and is projected to reach USD 833.9 million by the end of 2025, growing at a CAGR of 7.3% during 2018–2025.
The key factor bolstering the injectable nanomedicines market growth is increase in the incidence of chronic diseases like cancer, cardiovascular diseases, etc. Extensive R&D activities coupled with a lot of clinical trials is also aiding the growth of the market. In addition, the continuous growth in demand for minimally invasive treatments along with large patient pool of geriatric population has further fuelling the growth of global injectable nanomedicines market share.
Based on Drug Type, Liposomes segment held the largest market share in 2017 and is expected to dominate the market during the forecast period
The Liposomes segment is expected to dominate the market due to extensive R&D activities in liposomal drug delivery systems which further favour development of injectable nanomedicines. In addition, efficacy and improved disease management coupled with targeted drug delivery is expected to fuel the demand of injectable medicine. The Nanocrystals segment held the second largest market share in 2017 and is expected to grow at the fastest rate during the forecast period.
Download Exclusive Sample Copy of This Report at https://www.gmiresearch.com/report/global-injectable-nanomedicines-market-by-product/sample-request
Extensive Research and development for injectable nanomedicine coupled with growing funding on nanomedicine development is a major factor expected to drive the revenue growth of the global injectable nanomedicines market over the forecast period.
North America is the biggest market in 2017 due to factors such as a significantly high rate of incidence of cancer as well as cardiovascular diseases, growing demand for rapid R&D of novel nanomedicine in order to address unmet medical needs. Europe has registered a significant growth rate in global injectable nanomedicines market and held the second highest market shares in 2017. Asia-Pacific is expected to show promising growth in global injectable nanomedicines during 2018-2025 due to the increase in government and private funding on health care infrastructure along with the rising incidence of neurological disorders. Moreover, increasing adoption of nanomedicine for the treatment of cancer, diabetes, cardiovascular diseases and some infectious disease in the Asia-Pacific region would also contribute significantly to the market growth for injectable nanomedicines in the region.
Various notable players operating in the market include Merck & Co., Inc., Lupin, Pacira Pharmaceuticals Inc., Celgene Pharmaceutical Co. Ltd., Amgen, Inc., Janssen Biotech Inc., Pfizer Inc., Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Bausch & Lomb Inc. among others among others.
The global injectable nanomedicines market has been segmented based on product type, indication type and key geographies. Based on the product type, global injectable nanomedicines market has been segmented into liposomes, micelles, nanocrystals and others. Based on indication type, the market has been segmented into cancers, central nervous system diseases, cardiovascular diseases, inflammatory diseases and others.
Ask For Customized Report at https://www.gmiresearch.com/report/global-injectable-nanomedicines-market-by-product/request-for-customization
The research report “Global Injectable Nanomedicines Market” provides in-depth analysis of injectable nanomedicines market, globally, based on product type, indication and major geographies for the forecast period from 2018 to 2025. The report highlights the major market drivers fuelling the growth as well as challenges faced by the market participants. The research report provides market size and forecast for injectable nanomedicines market. The report also analyses the competitive landscape, major players and their strategies in 2018. The competitive landscape section of the report captures and highlights the recent developments in the market.
Key questions answered in this research report:
1- At what pace is injectable nanomedicines market growing, globally? What will be the growth trend in future?
2- What are the key drivers and restraints in the current market? What will be the impact of drivers and restraints over the coming years?
3- What are the regional revenue and forecast breakdowns? Which are the major regional revenue pockets for growth in the injectable nanomedicines market?
4- What are the various application areas and how they are poised to grow?
Preview Analysis of Global Injectable Nanomedicines Market by Product Type (Liposomes, Micelles, Nanocrystals, Others), By Indication Type (Cancers, Central Nervous System Diseases, Cardiovascular Diseases, Inflammatory Diseases, Others) and by Geography – Opportunities & Forecast, 2018-2025
https://www.gmiresearch.com/report/global-injectable-nanomedicines-market-by-product/
About GMI Research
GMI Research is a market research and consulting firm which provides research-based solutions to business executives and investment professionals so that they can make right business & investment decisions faster based on real facts. We help business leaders through independent fact-based insight, ensuring their business achieve success by beating the competition.
GMI Research leverages its industry expertise and experience to identify the industry trends, big opportunities and potential growth areas across industries. Our Syndicated reports provide actionable insights and covers industry trends, market drivers & restraints, macroeconomics factors, market estimates & forecasts, competitive landscape etc. which helps our clients to strengthen its market position by deploying specific strategies and actions that will lead to higher growth.
Media Contact
Company Name: GMI RESEARCH
Contact Person: Media Relations
Phone: +353 1 442 8820
Address:Level 1, The Chase Carmanhall Road, Sandyford Industrial Estate
City: Dublin
State: Dublin
Country: Ireland
Website: www.gmiresearch.com
Media Contact
Company Name: GMI RESEARCH
Contact Person: Sarah Nash
Email: Send Email
Phone: +353 1 442 8820
Address:Level 1, The Chase Carmanhall Road, Sandyford Industrial Estate
City: Dublin
State: Dublin
Country: Ireland
Website: www.gmiresearch.com